Quick Answer
Relay Therapeutics, Inc. reported Diluted EPS of $1.61 per share (loss) for fiscal year 2025.
Relay Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.61 | +31.8% |
| 2024 | -$2.36 | +15.4% |
| 2023 | -$2.79 | -7.7% |
| 2022 | -$2.59 | +32.2% |
| 2021 | -$3.82 | +29.3% |
| 2020 | -$5.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.43 | +31.7% | -4.9% |
| June 30, 2025 | -$0.41 | +40.6% | +10.9% |
| March 31, 2025 | -$0.46 | +25.8% | +27.0% |
| September 30, 2024 | -$0.63 | -16.7% | +8.7% |
| June 30, 2024 | -$0.69 | +14.8% | -11.3% |
| March 31, 2024 | -$0.62 | +20.5% | -14.8% |
| September 30, 2023 | -$0.54 | +28.9% | +33.3% |
| June 30, 2023 | -$0.81 | -14.1% | -3.8% |
- Relay Therapeutics, Inc. showed an increase of +31.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Relay Therapeutics, Inc.’s diluted eps has grown by 70.2% (from $5.40 per share (loss) to $1.61 per share (loss)).
- The most recent figure is from Relay Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: